Novelli Enrico M, Gladwin Mark T
Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Chest. 2016 Apr;149(4):1082-93. doi: 10.1016/j.chest.2015.12.016. Epub 2015 Dec 28.
In spite of significant strides in the treatment of sickle cell disease (SCD), SCD crises are still responsible for high morbidity and early mortality. While most patients initially seek care in the acute setting for a seemingly uncomplicated pain episode (pain crisis or vaso-occlusive crisis), this initial event is the primary risk factor for potentially life-threatening complications. The pathophysiological basis of these illnesses is end-organ ischemia and infarction combined with the downstream effects of hemolysis that results from red blood cell sickling. These pathological changes can occur acutely and lead to a dramatic clinical presentation, but are frequently superimposed over a milieu of chronic vasculopathy, immune dysregulation, and decreased functional reserve. In the lungs, acute chest syndrome is a particularly ominous lung injury syndrome with a complex pathogenesis and potentially devastating sequelae, but all organ systems can be affected. It is, therefore, critical to understand the SCD patients' susceptibility to acute complications and their risk factors so that they can be recognized promptly and managed effectively. Blood transfusions remain the mainstay of therapy for all severe acute crises. Recommendations and indications for the safest and most efficient implementation of transfusion strategies in the critical care setting are therefore presented and discussed, together with their pitfalls and potential future therapeutic alternatives. In particular, the importance of extended phenotypic red blood cell matching cannot be overemphasized, due to the high prevalence of severe complications from red cell alloimmunization in SCD.
尽管在镰状细胞病(SCD)的治疗方面取得了重大进展,但SCD危机仍然是高发病率和早期死亡率的原因。虽然大多数患者最初在急性情况下因看似不复杂的疼痛发作(疼痛危机或血管闭塞性危机)而寻求治疗,但这一初始事件是潜在危及生命并发症的主要危险因素。这些疾病的病理生理基础是终末器官缺血和梗死,以及红细胞镰变导致的溶血的下游效应。这些病理变化可急性发生并导致显著的临床表现,但往往叠加在慢性血管病变、免疫失调和功能储备降低的背景之上。在肺部,急性胸综合征是一种特别凶险的肺损伤综合征,发病机制复杂,后遗症可能具有毁灭性,但所有器官系统都可能受到影响。因此,了解SCD患者对急性并发症的易感性及其危险因素至关重要,以便能够及时识别并有效管理。输血仍然是所有严重急性危机治疗的主要手段。因此,本文将介绍并讨论在重症监护环境中最安全、最有效地实施输血策略的建议和指征,以及它们的陷阱和潜在的未来治疗选择。特别是,由于SCD中红细胞同种免疫严重并发症的高发生率,扩展表型红细胞匹配的重要性再怎么强调也不为过。